相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
Max M. Wattenberg et al.
BRITISH JOURNAL OF CANCER (2020)
Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation
Eileen M. O'Reilly et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
Michael J. Pishvaian et al.
LANCET ONCOLOGY (2020)
Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice?
Go Nishikawa et al.
CANCER (2020)
Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry
Ruth I. Tennen et al.
SCIENTIFIC REPORTS (2020)
NCCN: Continuing Education
Mary B. Daly et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
Praveen Vikas et al.
FRONTIERS IN ONCOLOGY (2020)
Olaparib for Metastatic Castration-Resistant Prostate Cancer
J. de Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The forefront of ovarian cancer therapy: update on PARP inhibitors
M. R. Mirza et al.
ANNALS OF ONCOLOGY (2020)
Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review
Ghulam Rehman Mohyuddin et al.
BMC CANCER (2020)
Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma
Giampaolo Perri et al.
JAMA SURGERY (2020)
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Florent Peyraud et al.
CANCERS (2020)
Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes
Keijiro Mizukami et al.
EBIOMEDICINE (2020)
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy
Robert M. Samstein et al.
NATURE CANCER (2020)
Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma
Andreas Seeber et al.
ESMO OPEN (2020)
Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors
Pascal Hammel et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
M. E. Robson et al.
ANNALS OF ONCOLOGY (2019)
PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
Man Yee T. Keung et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib
P. Hammel et al.
ANNALS OF ONCOLOGY (2019)
Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis
Taiane F. Rebelatto et al.
CANCER TREATMENT REVIEWS (2019)
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
I. Ray-Coquard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study
Nicolas Williet et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2019)
Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline BRCA or PALB2 Mutation
Shun Yu et al.
JCO PRECISION ONCOLOGY (2019)
Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study
Anas M. Saad et al.
BMC CANCER (2018)
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma
Maeve A. Lowery et al.
EUROPEAN JOURNAL OF CANCER (2018)
Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer
Chunling Hu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma
Alex B. Blair et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2018)
Biomarkers for Homologous Recombination Deficiency in Cancer
Michal M. Hoppe et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
Maeve A. Lowery et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Advanced pancreatic cancer: a meta-analysis of clinical trials over thirty years
Bradley R. Hall et al.
Oncotarget (2018)
Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer
Tomohiro Kondo et al.
Oncotarget (2018)
Biomarkers for Homologous Recombination Deficiency in Cancer
Michal M. Hoppe et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
Maeve A. Lowery et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Role of BRCA Mutations in the Modulation of Response to Platinum Therapy
Sanghamitra Mylavarapu et al.
FRONTIERS IN ONCOLOGY (2018)
Prospective Study of Germline Genetic Testing in Incident Cases of Pancreatic Adenocarcinoma
Randall Brand et al.
CANCER (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations
Kim A. Reiss et al.
JCO PRECISION ONCOLOGY (2018)
Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing
Diana Mandelker et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma
Koji Shindo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Hiro Sato et al.
NATURE COMMUNICATIONS (2017)
Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer
Talia Golan et al.
BRITISH JOURNAL OF CANCER (2017)
Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening
S. Paluch-Shimon et al.
ANNALS OF ONCOLOGY (2016)
Clinical outcomes in pancreatic adenocarcinoma associated with BRCA-2 mutation
Ojas Vyas et al.
ANTI-CANCER DRUGS (2015)
Prevalence of Germline Mutations in Cancer Predisposition Genes in Patients With Pancreatic Cancer
Robert C. Grant et al.
GASTROENTEROLOGY (2015)
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
Spring Holter et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell et al.
NATURE (2015)
Homologous Recombination and Human Health: The Roles of BRCA1, BRCA2, and Associated Proteins
Rohit Prakash et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2015)
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study
David B. Zhen et al.
GENETICS IN MEDICINE (2015)
Population Testing for Cancer Predisposing BRCA1/BRCA2 Mutations in the Ashkenazi-Jewish Community: A Randomized Controlled Trial
Ranjit Manchanda et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
T. Golan et al.
BRITISH JOURNAL OF CANCER (2014)
Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Kathryn P. Pennington et al.
CLINICAL CANCER RESEARCH (2014)
Pancreatic Adenocarcinoma
David P. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2
Efrat Gabai-Kapara et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
High Prevalence of BRCA1 and BRCA2 Germline Mutations with Loss of Heterozygosity in a Series of Resected Pancreatic Adenocarcinoma and Other Neoplastic Lesions
Aimee L. Lucas et al.
CLINICAL CANCER RESEARCH (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
Thomas Helleday
MOLECULAR ONCOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Screening for Founder Mutations in BRCA1 and BRCA2 in Unselected Jewish Women
Kelly A. Metcalfe et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control
Ramunas Janavicius
EPMA JOURNAL (2010)
BRCA Germline Mutations in Jewish Patients With Pancreatic Adenocarcinoma
Cristina R. Ferrone et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Genetic epidemiology of BRCA mutations - family history detects less than 50% of the mutation carriers
Pal Moller et al.
EUROPEAN JOURNAL OF CANCER (2007)
The prevalence of BRCA2 mutations in familial pancreatic cancer
Fergus J. Couch et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds
AP Klein et al.
CANCER RESEARCH (2004)
BRCA2 germline mutations in familial pancreatic carcinoma
SA Hahn et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin
A Bhattacharyya et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
